Breast Cancer
Access all ESMO scientific and educational resources on Breast Cancer
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Access all ESMO scientific and educational resources on Breast Cancer
From the 2021 World Conference on Lung Cancer:
Combining first-line chemotherapy with atezolizumab could improve outcomes for patients with nonsquamous non-small-cell lung cancer and asymptomatic brain metastases
From the 2021 World Conference on Lung Cancer:
Durvalumab given with or without tremelimumab may improve the outcomes of patients undergoing first-line treatment for metastatic non-small-cell lung cancer
Receipt of total abdominal hysterectomy with chemotherapy may improve survival compared with chemotherapy alone in women with uterine cancer whose disease has spread to distant organs
Adding ipilimumab to nivolumab does not extend overall survival for stage IV squamous non-small-cell lung cancer patients who have progressed after chemotherapy
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.